Short term effect of Docetaxel combined with Carboplatin in the treatment of breast cancer patients with pulmonary metastasis and its impact on survival
YE Zhenjun ZHOU Yuan
The Fourth Department of Internal Medicine, the Sixth People′s Hospital of Huizhou City, Guangdong Province, Huizhou 516211, China
Abstract：Objective To investigate the Short term effect of Docetaxel combined with Carboplatin in the treatment of breast cancer patients with pulmonary metastasis and its impact on survival. Methods A total of 72 patients with lung metastasis of breast cancer admitted to the Sixth People′s Hospital of Huizhou City from January 2019 to January 2020 were selected as the research objects. They were divided into control group and research group by ball-touching method, with 36 patients in each group. The control group was treated with Carboplatin combined with Paclitaxel, and the study group was treated with Carboplatin combined with Docetaxel. The short-term efficacy, survival and adverse drug reactions of the two groups were compared. Results The objective effective rate of study group was higher than that in control group, and the difference was statistically significant (P<0.05). There was no significant difference in disease control rate between two groups (P>0.05). There was no significant difference in overall survival rate between the two groups (P>0.05). In terms of adverse reactions, there was no significant difference in the incidence of liver function damage, diarrhea, nausea and vomiting between the two groups (P>0.05). The incidence of hand-foot syndrome and leukopenia in the study group was lower than that in the control group, and the difference was statistically significant (P<0.05). Conclusion Combined treatment of Carboplatin and Docetaxel in patients with lung metastasis of breast cancer can improve the short-term objective response rate of patients, with higher safety and fewer side effects.
叶振君； 周园. 多西紫杉醇联合卡铂治疗乳腺癌肺转移患者的近期效果及对生存情况的影响[J]. 中国当代医药, 2022, 29(20): 95-97.
YE Zhenjun； ZHOU Yuan. Short term effect of Docetaxel combined with Carboplatin in the treatment of breast cancer patients with pulmonary metastasis and its impact on survival. 中国当代医药, 2022, 29(20): 95-97.
Stefanou D，Kokkali S，Tripodaki ES，et al.Subcutaneous Trastuzumab Combined with Pertuzumab and Docetaxel as First-line Treatment of Advanced HER2-positive Breast Cancer[J].Anticancer Res，2018，38（11）：6565-6569.
Liu YC，Ma Y，An N，et al.Clinical efficacy of combination of pertuzumab，trastuzumab，and docetaxel for treatment of patients with HER2-positive breast cancer[J].Medicine，2019， 98（38）：e17262.
京公网安备 11010502046607号